About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.

Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.

NCT00195325·3 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Wyeth is now a wholly owned subsidiary of Pfizer

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Documented diagnosis of malignant solid tumor with measurable disease
Life expectancy of at least 12 weeks
ECOG (The Eastern Cooperative Oncology Group scale) performance status of 0, 1, or 2

You may not be if

Recent major surgery, radiation therapy or anti-cancer treatment
History of any other prior malignancy within the last 5 years

The record

StatusTerminated

PhasePhase 1

Taking part45

StartedAug 2005

UpdatedMar 26, 2007

Conditions

Tumors Neoplasms

Where3

Lexington, Kentucky, United States
Cleveland, Ohio, United States
Nashville, Tennessee, United States